Epitel, a president in AI systems for patient-focused mental wellness options, has appointed Ken Nelson, a pioneer in the gadgets business, to its board of directors. With his expertise in rural patient monitoring, medical devices, and digital health, Nelson will have a significant impact on helping Epitel advance as the business continues to redefine the field of brain monitoring using AI/ML and its wearable EEG technology.

Ken Nelson, a pioneer in developing teams and leading corporate initiatives for cutting-edge technologies in the wearables and distant individual checking sectors, brings a wealth of knowledge with over 20 years of experience and extensive expertise. His broad business leadership experience includes key roles in creating infrastructure for leading market players in electronic health and cardiovascular remote patient monitoring.

His significant efforts include serving as World VP of Sales at BioTelemetry, VP of Sales &amp, Marketing at iRhythm, and Chief Commercial Officer at Bardy Diagnostics. He most recently held the position of Mind of Digital Health, Diagnostics, and Monitoring at Biotronik. His career features include leading business work that contributed to effective IPOs and mergers, including BioTelemetry’s 2.8 billion USD acquisition by Philips and Bardy Diagnostics ‘ 450 million USD consolidation by HillRom/Baxter.

” Ken Nelson brings a wealth of knowledge and a proven track record in the MedTech and digital health areas”, said Mark Lehmkuhle, CEO of Epitel. His proper judgment and leadership will be very useful as we continue to develop our AI-based mental health options and develop our impact on patient care. Ken has been a wonderful addition to our Board of Directors.

Nelson is a companion in the Medtech Advantage Fund, which has an exclusive agreement with Medtech Innovator, the largest global pedal for MedTech and Digital Health startups. In addition, he serves as Chairman of the Board for CardiaCare and is an active board member for HeartBeam ( NASDAQ: BEAT ), Happitech, and several other disruptive cardiac Digital Health and MedTech startups.

Nelson is also involved with advisory boards and planning committees for SmartCardia, HeartX, HRX ( Digital Health Summit of Heart Rhythm Society ), and the American Heart Association’s Health Tech Innovation Business Advisory Board and Heart &amp, Brain Accelerator.

Nelson stated that with the FDA-approved technology that Epitel is bringing to industry, we may fundamentally alter the standard of care for mental health monitoring, with a concentrate on epilepsy patients and their monitoring before moving on to other areas like EEG and brain health monitoring. My understanding of how to create a multi-billion industry for respiratory digital health and distant patient monitoring of ECGs is a great illustration of how Epitel can step up and take the lead in the EEG checking space.

Nelson joins a solid consulting group that includes CEO Mark Lehmkuhle, Vikram Chaudhery of Genoa Ventures, and Josh Phillips of Catalyst Health Ventures.